Search the Newsreel

Ascentage Pharma Group International (AAPG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Ascentage Pharma Group International (AAPG), detailing its current stock price, market capitalization, and recent trading activity. It highlights the company's financial information, discussions, and analysis resources available on TradingKey, and emphasizes the general nature of the investment information …

Central Garden & Pet to Announce Q3 Fiscal 2026 Financial Results

WALNUT CREEK, Calif., July 28, 2026--(BUSINESS WIRE)--Central Garden & Pet Company (NASDAQ: CENT) (NASDAQ: CENTA) ("Central"), a leading consumer goods company in the pet and garden industries, will release its fiscal 2026 third quarter results for the period ending June 27, 2026, after market …

Central Garden Expands Europe Pet Business With TRIXIE Acquisition

Central Garden & Pet Company CENT has entered into a definitive agreement to acquire a majority stake in TRIXIE Heimtierbedarf GmbH & Co. KG, Europe's leading pet supplies and pet snacks company. The transaction marks an important step in expanding Central Garden's European footprint …

Ascentage Pharma Group International (AAPG) Income Statement

This article provides key financial insights into Ascentage Pharma Group International (AAPG) through its income statement, offering both quarterly and annual data. It includes FAQs explaining how to interpret the income statement, distinguishing between quarterly and annual reports, and identifying the most critical metrics …

Central Garden & Pet Company entered into a definitive agreement to acquire 80% stake in Trixie Heimtierbedarf GmbH & Co. Kg for ?400 million.

Central Garden & Pet Company has agreed to acquire an 80% stake in Trixie Heimtierbedarf GmbH & Co. Kg for €400 million, comprising a €340 million cash payment and a €60 million earnout. Trixie's current leadership team will remain, with minority shareholders Dirk Jessen …

Central Garden & Pet to acquire majority stake in TRIXIE By Investing.com

Central Garden & Pet Company announced its definitive agreement to acquire a majority interest in TRIXIE Heimtierbedarf GmbH & Co. KG, a European pet supplies company. This acquisition will strengthen Central Garden & Pet's presence in the European pet market, adding TRIXIE's extensive product …

Central Garden & Pet’s TRIXIE Deal Targets European Pet-Supplies Leadership

Key Points Interested in Central Garden & Pet Company? Here are five stocks we like better. Central Garden & Pet agreed to acquire a majority stake in Germany's TRIXIE, valuing the deal at a high-single-digit multiple before synergies. Management says the combination could create …

Central Garden & Pet Company to Acquire Majority Stake in European Pet Supplies Leader TRIXIE for Up to €400 Million

Central Garden & Pet Company announced its agreement to acquire approximately 80% of TRIXIE Heimtierbedarf GmbH & Co. KG, a prominent European pet supplies manufacturer, for up to €400 million. This acquisition, comprising an upfront cash payment of €340 million and potential earn-out consideration …

Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know

Ascentage Pharma Group International - Unsponsored ADR (AAPG) closed the last trading session at $18.29, gaining 9.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any …

Ascentage Pharma Group International (AAPG) Cash Flow

This article provides an overview of Ascentage Pharma Group International's (AAPG) cash flow, detailing its operating, investing, and financing activities. It explains what each type of cash flow represents and how much the company generated or used in recent fiscal periods. Key financial figures …

Central Garden & Pet to acquire majority stake in TRIXIE

Central Garden & Pet Company announced its definitive agreement to acquire a majority interest in TRIXIE Heimtierbedarf GmbH & Co. KG, a European pet supplies and snacks company. This acquisition will expand Central's Pet segment and increase its international sales to approximately 10% of …

Central Garden & Pet To Acquire A Majority Interest In TRIXIE Heimtierbedarf GmbH & Co. KG, Europe’s Leading Pet Supplies And Pet Snacks Company

Central Garden & Pet Company announced its definitive agreement to acquire a majority interest in TRIXIE Heimtierbedarf GmbH & Co. KG, a leading European pet supplies and snacks company. This acquisition will expand Central's presence in Europe and strengthen its pet portfolio, with TRIXIE's …

Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.2% - What's Next?

AAPG|Ascentage Pharma Group International|Price:18.290|Chg%:-0.615

This article provides a financial summary of Ascentage Pharma Group International (AAPG), highlighting its stock price, market capitalization, and upcoming earnings report. It emphasizes the availability of financial analysis tools on TradingKey, allowing investors to review income statements, balance sheets, and cash flow statements. …

Ascentage CEO ranks No. 3 in small molecules on list of 60 leaders

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category among 60 global pharmaceutical leaders. The recognition highlights his leadership in developing a small-molecule oncology pipeline, including …

ETFs Investing in Central Garden & Pet Company Class A Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Central Garden & Pet Company Class A (CENTA) stocks. The list is sorted by market value and includes various details for each ETF, such as weight, issuer, management style, focus, expense …

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 87.2% in July

Ascentage Pharma Group International (NASDAQ:AAPG) experienced a significant 87.2% decline in short interest during July, falling to 20,246 shares as of July 15th. Despite this reduction, analysts maintain a bullish outlook with a consensus "Buy" rating and an average price target of $46.43, even …

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why

Ascentage Pharma Group International (NASDAQ:AAPG) shares gapped down prior to trading on Friday, opening at $18.52 after closing at $19.33, and later trading around $18.07. Despite this dip, Wall Street analysts maintain a bullish outlook with a consensus "Buy" rating and a price target …

Central Garden & Pet faces stagnant growth and margin pressure, limiting near-term returns despite cheap valuation.

Central Garden & Pet Company has been rated 'Hold' due to stagnant growth in its pet segment and margin compression in its garden segment, despite revenue gains. The company trades below sector multiples, but concerns persist regarding sustainable profitability and cautious full-year guidance from …

Central Garden & Pet Company: This Is Far From A Strong Growth Play (NASDAQ:CENT)

Responsive Playbooks and the CENTA Inflection

This article provides an AI-generated analysis for Central Garden & Pet Company (NASDAQ: CENTA), indicating a neutral near and mid-term outlook with a positive long-term bias. It outlines detailed institutional trading strategies, including long, breakout, and short positions, alongside multi-timeframe signal analysis for various …

Ascentage Pharma Group Internat (AAPG) Stock Analysis: Uncovering a Potential 158% Upside

Ascentage Pharma Group International (AAPG) is a clinical-stage biotechnology company focused on cancer, chronic hepatitis B, and age-related diseases, showing potential for significant growth. Analysts project a potential upside of 158.88% despite the company currently being in a developmental phase with negative earnings and …

Ascentage Pharma Sets Up $200 Million Nasdaq ATM Offering Program

Ascentage Pharma Group International has established a $200 million At-The-Market (ATM) offering program on Nasdaq. The biopharmaceutical company filed a shelf registration statement with the SEC to enable flexible capital raising in the U.S. market through the sale of American depositary shares. This move …

CENTA Q2 2026 Earnings: EPS Surges Past Estimates Amid Pet Segment Strength - Earnings Momentum Score

Ascentage Pharma (NASDAQ: AAPG) targets US$200M ATM ADS sale

Ascentage Pharma Group International plans an at-the-market (ATM) equity program to sell up to US$200 million in American depositary shares (ADSs) on Nasdaq through Citigroup, Deutsche Bank, and BTIG. The proceeds are intended to fund research and development, clinical trials, commercialization, and general corporate …

Allspring Global Investments Holdings LLC Has $56.84 Million Stock Position in Central Garden & Pet Company $CENTA

Central Garden & Pet (GP7) Q4 2024 Earnings Report - Results, Call & Slides

Central Garden & Pet (GP7) reported its Q4 2024 earnings, beating EPS expectations by €0.03 with an actual EPS of -€0.16 against a consensus of -€0.19. However, the company missed revenue estimates, reporting €585.20M against an expected €618.72M, marking a -10.75% year-over-year decline. The …

Centaurus Metals Limited (ASX:CTM): Are Analysts Optimistic?

Centaurus Metals Converts 20,833 Options at $0.50 Each, Lifting Ordinary Shares on Issue to 566.6 Million

Centaurus Metals (ASX:CTM) Gains After Major Development Update for Jaguar Nickel Project

Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation

Centaurus Metals (ASX:CTM) Rallies to Year High – What’s Driving the Momentum

Centaurus Metals (ASX:CTM) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Centaurus Metals' (ASX:CTM) Cash Burn Rate

Analysts Have Lowered Expectations For Ascentage Pharma Group International (HKG:6855) After Its Latest Results

Ascentage Pharma: 2025 revenue fell 41.5% to RMB574.1M, net loss rose to RMB1,243.0M, and liquidity improved via IPO and Takeda deal